CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

Last week was another busy week for the White House, with several notable Executive Orders and more agency leadership changes ...

Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its ...

The widely followed cryptocurrency analyst Benjamin Cowen is warning that Ethereum (ETH) could slide further against Bitcoin ...

TD Cowen maintained a positive stance on Planet Fitness (NYSE:PLNT) shares, reiterating a Buy rating and a price target of ...

However, 10 companies defied a broader market optimism, mostly due to a series of stock rating downgrades from investment ...

China-based GDS Holdings (GDS) is surging 6% after investment bank TD Cowen raised its price target on the shares. The ...

TD Cowen had upgraded Merck in early 2024 based on confidence in Keytruda and Gardasil’s performance, a lack of binary risks, and an attractive valuation. However, setbacks in Gardasil’s China sales ...

TD Cowen analyst John Kernan maintained a Hold rating on Under Armour (UAA – Research Report) today and set a price target of $10.00. The ...

Closely followed crypto analyst Benjamin Cowen says that a shift in monetary policy will most likely be what finally triggers an "altseason," or a period where altcoins vastly outperform Bitcoin (BTC) ...

TD Cowen analyst Andrew Kligerman maintained a Hold rating on AFLAC (AFL – Research Report) today and set a price target of $98.00. The ...